- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Drug Alert: CDSCO flags 83 formulations as not of standard quality
Overview
In its latest drug safety alert, the apex drug regulatory body, Central Drugs Standard Control Organization (CDSCO) has flagged 83 medicine batches for failing to qualify for a random drug sample test for the month of November, 2022.
These drugs samples which are declared not of standard quality include Pantop-DSR (Pantoprazole Sodium Gastro-resistant & Domperidone Prolonged- release Capsules IP) manufactured by Aristo Pharmaceuticals, SHELCAL-500 (Calcium And Vitamin D3 Tablets I.P.) manufactured by Pure and Cure Healthcare, Paracetamol Tablets IP 650mg manufactured by ANG Lifesciences India, Montelukast Sodium Tablets IP 5 mg manufactured by Skymap Pharmaceuticals and others.
For more details, check out the link given below:
83 Drug Samples Fail To Qualify CDSCO Test
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)